APTA Therapeutics is pioneering therapies for regulatory autoantibody–driven diseases, addressing an immune pathway still lacking targeted treatment options.
Regulatory autoantibodies (RAbs) are naturally occurring autoantibodies that target G protein coupled receptors (GPCRs) exerting physiological and homeostatic effects by altering receptor activity, signaling pathways, and immune responses. However, under certain conditions, these regulatory autoantibodies may become pathogenic in nature triggering the development of various diseases, including autoimmune disorders, cardiovascular disease, neuropsychiatric syndromes, and post-viral sequelae. Altered signaling of GPCRs caused by pathogenic RAbs appears to be a key step in the development of RAb related diseases.
APTA Therapeutics is a pioneering clinical-stage biopharmaceutical company dedicated to transforming the treatment of diseases caused by regulatory autoantibodies.
Regulatory autoantibodies binding to G protein-coupled receptors are increasingly recognized as potential key drivers of various diseases.
APTA Therapeutics is currently focused on the clinical development of rovunaptabin in heart failure and in post viral infectious diseases.